[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-bundle-branch-pacing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-bundle-branch-pacing":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,75,120,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100619283","safety-and-performances-of-the-linea-cardiac-pacing-lead-optimized-for-the-implantation-in-interventricular-septum-100619283",false,"NCT07342608","Safety and Performances of the LINEA Cardiac Pacing Lead Optimized for the Implantation in Interventricular Septum","STARLIGHT","Inclusion criteria (phase I and II):\n\n* Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)\n* Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM\n* Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area\n* Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated\n\nExclusion criteria (phase I and II):\n\n* Patient planned for a device upgrade, or a device or a lead replacement\n* Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy\n* Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%\n* Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)\n* Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)\n* Patient with a life expectancy of less than 2 years\n* Minor age patient (i.e. under 18 years of age)\n* Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation\n* Non-menopausal women","ALL","18 Years",{"count":19,"type":20},450,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.",[26,27,28],"Bradycardia","Left Bundle Branch Area Pacing","Left Bundle Branch Pacing","NOT_YET_RECRUITING","2026-02-13",{"date":32,"type":33},"2026-02-17","ACTUAL",{"date":35,"type":20},"2026-03-31",{"date":37,"type":20},"2030-04-30",{"name":39,"class":40},"MicroPort CRM","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100621559","left-bundle-branch-pacing-in-patients-with-hypertrophic-cardiomyopathy-after-myectomy-100621559","NCT07372196","Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy","LEFTpaceHCM","Inclusion criteria:\n\n* Men and women aged 18 years and older;\n* Patients with post-myectomy HCM who develop LBBB with a QRS complex greater than 130 ms and a high risk of SCD (HCM Risk-SCD ≥ 6%);\n* Signed informed consent to participate in the study;\n\nExclusion criteria:\n\n* Absence of QRS complex morphology consistent with LBBB in LBBB with a positive QRS complex less than 130 ms;\n* Presence of baseline complete RBBB;\n* Heart transplantation or implantation of an LVAD is planned within the next 6 months;\n* Patients with intermediate or low risk of SCD;\n* History of AMI less than three months prior to study inclusion;\n* Acute renal and hepatic failure;\n* Acute infectious diseases;\n* Presence of mental illness;\n* Presence of other illnesses for which life expectancy is less than one year;\n* Patient refusal to participate in the study at any stage;","75 Years",{"count":50,"type":20},30,[23],"Pilot interventional randomized clinical trial to study the efficacy of left bundle branch pacing in patients with hypertrophic cardiomyopathy after myectomy for the prevention of progression of heart failure, prevent the occurrence of life-threatening rhythm disturbances and promote reverse remodeling of the LV.\n\nThe aim of the study is to evaluate the comparative efficacy and safety of implantation of a cardioverter-defibrillator with left bundle branch block pacing and a dual-chamber cardioverter-defibrillator in patients with HCM and complete left bundle branch block after myectomy at high risk of SCD.\n\nObjectives of the study:\n\n1. To analyze the safety of ICD implantation procedures with LBBB pacing in patients with HCM and LBBB after myectomy at high risk of SCD;\n2. To develop a technique for LBBB lead implantation in patients with HCM and LBBB after myectomy;\n3. To conduct a comparative analysis of QRS complex duration data based on ECG data before and after surgery, LV activation time, and pacing threshold based on postoperative programming data;\n4. To conduct a comparative analysis of the functional class of CHF, NT-proBNP, the presence\u002Fabsence of interventricular and intraventricular dyssynchrony, the degree of diastolic dysfunction, LVEF, and LV EDV based on echocardiography data before and 12 months after surgery;\n5. Conduct a comparative analysis of QRS complex duration data based on ECG data, LV activation time, pacing threshold, the presence of recorded episodes of AF, VT, VF, antitachycardia and shock therapy according to programming data at 3, 6, and 12 months after surgery;\n6. Assess quality of life before and 12 months after surgery using the KCCQ-12 questionnaire; 30 patients (15 patients in each group) will be randomly separated into 2 groups. All participants go through ICD programming at 3, 6, and 12 months after myectomy, assessment of left ventricular remodeling based on ECG and echocardiography, NT-proBNP, assessment of quality of life before surgery and 12 months after surgery.",[54,55,28,56,57],"HCM - Hypertrophic Cardiomyopathy","Sudden Cardiac Death","ICD","Heart Failure (HF)",[59,60,28,56,61,62],"sudden cardiac death","Hypertrophic Cardiomyopathy","Heart failure","myectomy","RECRUITING","2026-01-20",{"date":66,"type":33},"2026-01-28",{"date":68,"type":33},"2025-11-14",{"date":70,"type":20},"2027-07-01",{"name":72,"class":73},"Meshalkin Research Institute of Pathology of Circulation","NETWORK",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":74},"100616406","study-of-ahre-burden-in-patients-undergoing-bachmann-bundle-area-pacing-and-left-bundle-branch-pacing-100616406","NCT07305194","Study of AHRE Burden in Patients Undergoing Bachmann Bundle Area Pacing and Left Bundle Branch Pacing.","Study of Atrial High-Rate Episode Burden in Patients Undergoing Concurrent Bachmann Bundle Area Pacing and Left Bundle Branch Pacing , Compared With Either Left Bundle Branch Pacing or Conventional Right Ventricular Pacing.","AHRE-BLAST","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) with a clear indication for permanent pacing, according to ESC guidelines \\[15\\] for the management of conduction disturbances (e.g. symptomatic bradycardia, complete atrioventricular block, sinus node dysfunction).\n* Sinus rhythm at the time of implantation, with no documented episodes of atrial fibrillation prior to implantation, either in the medical history or in previous recordings (ECG, Holter, telemetry).\n* Ability to be followed up for at least 24 months after implantation.\n* Provision of written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* History of atrial fibrillation prior to implantation, either permanent or paroxysmal, documented on ECG, Holter, or telemetry.\n* Prior pharmacological or interventional treatment for AF (e.g. antiarrhythmic drugs, catheter ablation).\n* Inability to comply with long-term follow-up or non-adherence to follow-up visits.\n* Contraindications to pacemaker lead placement at the selected sites.\n* Participation in another study that could influence the results.\n* Previous device implantation.",{"count":84,"type":20},460,"24 Months","OBSERVATIONAL","This prospective observational study evaluates the burden of Atrial High-Rate Episodes (AHRE) in patients without a prior history of atrial fibrillation who undergo concurrent Bachmann Bundle Area Pacing (BBAP) and Left Bundle Branch Pacing (LBBP). Physiological pacing at these sites aims to improve interatrial conduction and reduce the risk of atrial arrhythmias.\n\nThe study includes a comparative assessment across three patient groups:\n\n1. BBAP + LBBP (physiological pacing group)\n2. Right Atrial Appendage (RAA) pacing + LBBP\n3. Conventional pacing - RAA and Right Ventricular (RV) pacing AHRE burden will be quantified via device diagnostics and remote monitoring at 3, 12 and 24 months post-implantation. Episodes will be classified by duration (0-6 min, 6-24 h, \\>24 h), differentiating subclinical AHRE from clinically documented AF.\n\nSecondary analyses include electrocardiographic changes (P-wave indices), the need for antiarrhythmic therapy, and comprehensive echocardiographic evaluation of atrial function (e.g., LA strain, conduction delays, LAVI).\n\nThe study aims to determine whether physiological pacing (BBAP + LBBP) provides superior protection against AHRE development compared with RAA + LBBP and conventional pacing strategies.",[89,90,91,28,92],"Atrial Arrhythmia","Atrial Fibrillation (AF)","Pacemaker Implantation","Conduction System Pacing",[94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109],"Atrial High-Rate Episodes (AHRE)","Subclinical Atrial Fibrillation","Bachmann Bundle Area Pacing (BBAP)","Left Bundle Branch Pacing (LBBP)","Physiological Pacing","Interatrial Conduction","Atrial Synchrony","P-wave Duration","Atrial Electromechanical Remodeling","Atrial Strain","Left Atrial Reservoir Strain","Inter-atrial Conduction Delay (IACD)","Speckle Tracking Echocardiography","Left Atrial Volume Index (LAVI)","Atrial Arrhythmias","Device-Detected AF","2025-12-11",{"date":112,"type":33},"2025-12-26",{"date":114,"type":20},"2026-01-01",{"date":116,"type":20},"2028-04-14",{"name":118,"class":119},"University Hospital of Patras","OTHER",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":74},"100611789","redo-af-randomized-evaluation-of-dual-options-for-af-re-intervention-100611789","NCT07245147","REDO-AF: Randomized Evaluation of Dual Options for AF Re-intervention","REDO-AF","Inclusion Criteria:\n\n* One or more prior left atrial (LA) ablation procedure(s) for AF\n* Symptomatic AF\u002Fatypical atrial flutter\u002Fatrial tachycardia with failure of or intolerance to medical rate or rhythm control therapy, that is detected at \\>2 months post most recent LA ablation procedure\n* Either a LA volume index on any prior echo of \\>= 45ml\u002Fm2 or LA diameter \\>= 50mm OR a HATCH score \\>=2 (where 1 point is given for each for hypertension, Age\\>75, COPD, and 2 points for each of stroke\u002FTIA, or HF (defined as signs or symptoms of pulmonary edema and may include HFrEF or HFpEF)\n* Be considered suitable for both treatment strategies of redo ablation and pacemaker and AV node ablation\n* Willingness to participate, complete the QOL questionnaires and ability to sign informed consent\n\nExclusion Criteria:\n\n* Severe valvular disease defined by echo criteria\n* Myocardial infarction, stroke, or coronary revascularization within the previous 3 months\n* LVEF \\\u003C40% or need for an ICD\n* Life expectancy \\\u003C24 months\n* Lack of capacity to consent",{"count":128,"type":20},16,[23],"The goal of this randomized open-label clinical trial is to evaluate two different strategies for the treatment of recurrent atrial fibrillation (AF) after AF ablation. Patients who have symptomatic, drug-refractory recurrence of AF will be randomized to either a redo AF ablation vs conduction system pacing with AV node ablation. Patients will need to have undergone at least 1 prior AF ablation to be considered eligible for the study. The current trial is a vanguard study of 16 patients and will determine the feasibility of enrolment, compare changes in quality of life, and inform the design of the definitive REDO AF trial.",[90,132,28],"AV Node Ablation",[134,135,136,137,138,139],"Atrial fibrillation","pace and ablate","AV node ablation","Left bundle branch pacing","LBBP","Redo","2025-11-20",{"date":142,"type":33},"2025-11-24",{"date":144,"type":20},"2025-11",{"date":146,"type":20},"2027-09",{"name":148,"class":119},"Jacqueline Joza",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":74},"100551563","left-bundle-branch-area-pacing-3d-guidance-system-100551563","NCT06461715","Left Bundle Branch Area Pacing 3D Guidance System","Left Bundle Branch Area Pacing Study Designing the 3D Hybrid Guidance System for Implantation of Cardiac Devices","Inclusion Criteria:\n\n* All patients who took part in the TACTIC-CRT (IRAS 250715) and Cardiac CT to guide Cardiac Resynchronisation Therapy (CRT) implantation (IRAS 150161) study.\n* All patients who received a LBBA pacing device from the GSTT\u002FRBH\u002FICH database in the last 10 years (from 01\u002F01\u002F2014) and had a cardiac MRI for assessment of scar.\n* All patients who are \\>18 years old.\n* Male and Female\n\nExclusion Criteria:\n\n* All patients \\\u003C18 years old\n* Patients with congenital heart disease\n* Patients who did not have a cardiac MRI before receiving a LBBA pacing device",{"count":157,"type":20},300,"The investigator's project proposes the development of a 3D hybrid guidance system which has the aim of avoidance of scar and septal perforation through targeted lead deployment via a personalised septal real time image overlay onto x-ray fluoroscopy imaging during left bundle branch pacing. The investigators hypothesise that the use of cardiac anatomy and myocardial scar distribution derived from cardiac magnetic resonance imaging (MRI) as well as 3D position of the pacing lead, may improve LBBAP lead deployment success and improve clinical outcomes by guiding the physician towards optimal lead positioning.",[28,160,26],"Heart Failure",[137,162,163,164],"Pacemaker","Artificial intelligence","Conduction system pacing","2024-06-14",{"date":167,"type":33},"2024-06-17",{"date":169,"type":20},"2024-07-01",{"date":171,"type":20},"2025-05-31",{"name":173,"class":119},"Guy's and St Thomas' NHS Foundation Trust"]